A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability,
pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with
large granular lymphocytic leukemia or cytotoxic lymphomas